Chetty Terusha, Thorne Claire, Coutsoudis Anna
Africa Health Research Institute, Mtubatuba, KwaZulu-Natal, South Africa.
Department of Public Health Medicine, School of Nursing and Public Health, University of KwaZulu-Natal, Durban, KwaZulu-Natal, South Africa.
PLoS One. 2018 Feb 22;13(2):e0192805. doi: 10.1371/journal.pone.0192805. eCollection 2018.
Increasingly more women conceive on antiretroviral therapy (ART) with non-nucleoside reverse transcriptase-based regimens. This study assessed the effect of preconception tenofovir disoproxil fumarate (TDF)-lamivudine (3TC)/emtricitabine (FTC)-efavirenz (EFV) and post-conception TDF-(3TC/FTC)-EFV (versus other regimens) on preterm delivery (PTD) and small-for-gestational age (SGA) births.
We analysed data of 2549 HIV-infected women attending antenatal clinics in KwaZulu-Natal from 2010 through 2015 in this retrospective cohort study. Preconception, TDF-(3TC/FTC)-EFV was compared to nevirapine (NVP)-based regimens and other 3-drug EFV-based regimens. Post-conception, TDF-(3TC/FTC)-EFV was compared to NVP-based ART and zidovudine (ZDV) prophylaxis. Outcomes included PTD <37 weeks and SGA births. Generalized linear mixed effects were used to fit logistic regression models to account for repeat pregnancies.
Among 2549 singleton live births, 10.4% (n = 264) were PTD and 10.4% (n = 265) SGA. PTD declined from 16.3% in 2010 to 9.3% in 2015 and SGA remained stable from 9.9% in 2010 to 10% in 2015. Preconception NVP-based regimens [adjusted odds ratio (aOR) 0.66; 95% CI 0.27-1.63] and other 3-drug EFV-based regimens (aOR 0.72; 95% CI 0.24-2.12) were not associated with PTD versus TDF-(3TC/FTC)-EFV. NVP-based (aOR 0.75; 95% CI 0.40-1.42) and other 3-drug EFV-based regimens (aOR 1.55; 95% CI 0.76-3.16) were not associated with SGA births versus TDF-(3TC/FTC)-EFV. Post-conception NVP-based ART (1.77; 95% CI 0.89-3.51) and ZDV (1.03; 95% CI 0.68-1.58) were not associated with PTD versus TDF-(3TC/FTC)-EFV. NVP-based ART (1.55; 95% CI 0.66-3.61) and ZDV (0.89; 95% CI 0.53-1.47) were not associated with SGA versus TDF-(3TC/FTC)-EFV.
Preconception TDF-(3TC/FTC)-EFV and post-conception TDF-(3TC/FTC)-EFV were not associated with PTD or SGA, compared with other regimens. Increasing ART use merits further study of the optimum ART regimen for safe birth outcomes.
越来越多的女性在接受基于非核苷类逆转录酶的抗逆转录病毒疗法(ART)时怀孕。本研究评估了孕前替诺福韦酯(TDF)-拉米夫定(3TC)/恩曲他滨(FTC)-依非韦伦(EFV)以及孕后TDF-(3TC/FTC)-EFV(与其他方案相比)对早产(PTD)和小于胎龄(SGA)儿出生的影响。
在这项回顾性队列研究中,我们分析了2010年至2015年在夸祖鲁-纳塔尔省产前诊所就诊的2549名感染HIV的女性的数据。孕前,将TDF-(3TC/FTC)-EFV与基于奈韦拉平(NVP)的方案以及其他基于三种药物的EFV方案进行比较。孕后,将TDF-(3TC/FTC)-EFV与基于NVP的ART和齐多夫定(ZDV)预防方案进行比较。结局包括孕周<37周的早产和SGA儿出生。使用广义线性混合效应来拟合逻辑回归模型,以考虑重复妊娠的情况。
在2549例单胎活产中,10.4%(n = 264)为早产,10.4%(n = 265)为SGA儿。早产率从2010年的16.3%降至2015年的9.3%,SGA儿出生率从2010年的9.9%稳定至2015年的10%。与TDF-(3TC/FTC)-EFV相比,孕前基于NVP的方案[调整优势比(aOR)0.66;95%置信区间(CI)0.27 - 1.63]和其他基于三种药物的EFV方案(aOR 0.72;95% CI 0.24 - 2.12)与早产无关。与TDF-(3TC/FTC)-EFV相比,基于NVP的方案(aOR 0.75;95% CI 0.40 - 1.42)和其他基于三种药物的EFV方案(aOR 1.55;95% CI 0.76 - 3.16)与SGA儿出生无关。孕后,与TDF-(3TC/FTC)-EFV相比,基于NVP的ART(1.77;95% CI 0.89 - 3.51)和ZDV(1.03;95% CI 0.68 - 1.58)与早产无关。与TDF-(3TC/FTC)-EFV相比,基于NVP的ART(1.55;95% CI 0.66 - 3.61)和ZDV(0.89;95% CI 0.53 - 1.47)与SGA儿无关。
与其他方案相比,孕前TDF-(3TC/FTC)-EFV和孕后TDF-(3TC/FTC)-EFV与早产或SGA儿无关。增加ART的使用值得进一步研究以确定实现安全分娩结局的最佳ART方案。